SEC Form 4 · accession 0001140361-18-014256

BIOMARIN PHARMACEUTICAL INC · BMRN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Mar 15, 2018

Accepted (ET)

Mar 20, 2018 · 2:16 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001048477

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2,F1	Mar 15, 2018	M	15,000	$38.59	A	279,674	D
Common Stock^F2,F1,F3	Mar 15, 2018	S	15,000	$84.7267	D	264,674	D
Common Stock^F1	Mar 15, 2018	F	14,908	$83.57	D	249,766	D
Common Stock^F1,F4	Mar 15, 2018	A	46,340	$0.00	A	296,106	D
Common Stock	holding	—	—		—	182,201	I	Shares held by Jean-Jacques Bienaime Family Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to buy Common Stock)^F2,F1	$38.59	Mar 15, 2018	M	15,000	A	Nov 22, 2008	May 21, 2018	Common Stock	15,000	157,500	D
Stock Option (Right to buy Common Stock)^F1,F5	$83.57	Mar 15, 2018	A	148,190	A	Mar 15, 2019	Mar 14, 2028	Common Stock	148,190	148,190	D

F1This transaction, originally due to be reported on Monday, March 19, 2018, is being reported late due to an administrative oversight.
F2Trade made pursuant to a 10b5-1 plan executed on November 14, 2017.
F3The price in column 4 is the weighted average price. The price actually received ranged from $84.26 to $85.91. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F4Restricted stock units granted on March 15, 2018. Price not applicable.
F5Option grant vests 12/48th on March 15, 2019 and 1/48th on the 15th day of each month thereafter.